Reporting from the ESMO Congress 2021, Elizabeth Smyth comments on the updated results from the CheckMate 649 in advanced gastric, GEJ and oesophageal cancer that confirm chemotherapy + nivolumab as a new standard of care, while the new results of the immunotherapy combination arm show a possible benefit for subgroups of patients only. She further discusses the encouraging results from second line treatment with trastuzumab deruxtecan in patients with HER2-positive gastric cancer. Finally, she explains the encouraging results of the CLDN 18.2-targeted CAR-T cell therapy in digestive cancers.
LBA7 - First Report of Nivolumab (NIVO) Plus Ipilimumab (IPI) vs Chemotherapy (chemo) and Long-Term Follow-Up of NIVO Plus Chemo vs Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): CheckMate 649 Study - Dr Yelena Janjigian, US
LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen - Prof. Eric Van Cutsem, BE
1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system - Dr. Changsong Qi, CN
This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.